​

Atrium Therapeutics (RNA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

RNA Stock Forecast

Atrium Therapeutics (RNA) stock forecast, based on 16 Wall Street analysts, predicts a 12-month average price target of $22.50, with a high of $25.00 and a low of $15.00. This represents a 174.39% increase from the last price of $8.20.

$5 $14 $23 $32 $41 $50 High: $25 Avg: $22.5 Low: $15 Last Closed Price: $8.2

RNA Stock Rating

Atrium Therapeutics stock's rating consensus is Buy, based on 16 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (50.00%), 8 Hold (50.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 16 0 8 8 Strong Sell Sell Hold Buy Strong Buy

RNA Price Target Upside V Benchmarks

TypeNameUpside
StockAtrium Therapeutics174.39%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts124
Avg Price Target$15.00$20.00$22.50
Last Closing Price$8.20$8.20$8.20
Upside/Downside82.93%143.90%174.39%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26-4---4
Sep, 26-4---4
Aug, 26-3---3
Jul, 26-3---3
Jun, 26-2---2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 22, 2026Boobalan PachaiyappanRoth Capital$15.00$8.0087.50%82.93%
Aug 06, 2026H.C. Wainwright$25.00$11.74112.95%204.88%
Jun 18, 2026Cantor Fitzgerald$25.00$12.48100.32%204.88%
May 15, 2026Leerink Partners$25.00$13.2788.39%204.88%
Dec 18, 2025Evercore ISI$72.00$72.11-0.15%778.05%
Oct 28, 2025Keay NakaeChardan Capital$72.00$70.002.86%778.05%
Oct 28, 2025Luca IssiRBC Capital$72.00$70.002.86%778.05%
Oct 28, 2025Keay NakaeLoop Capital Markets$72.00$70.002.86%778.05%
Oct 27, 2025Market PerformLeerink Partners$72.00$69.952.93%778.05%
Oct 27, 2025Boobalan PachaiyappanRoth Capital$72.00$49.1546.49%778.05%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 22, 2026Roth CapitalBuyinitialise
Oct 15, 2026Cantor FitzgeraldOverweightOverweighthold
Aug 06, 2026H.C. WainwrightBuyinitialise
Jun 18, 2026Cantor FitzgeraldOverweightinitialise
Nov 12, 2025Cowen & Co.HoldHoldhold
Oct 29, 2025Cowen & Co.BuyHolddowngrade
Oct 28, 2025RBC CapitalSector Performdowngrade
Oct 27, 2025CitigroupBuyNeutraldowngrade
Oct 27, 2025Roth CapitalNeutraldowngrade
Oct 27, 2025CitigroupBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 $2 $3 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.85$-3.34$-2.91$-2.89$-4.97---
Avg Forecast$-2.73$-3.36$-2.65$-2.87$-3.30$-3.57$-1.85$1.53
High Forecast$-2.11$-2.07$-1.86$-2.70$-2.45$-2.17$-0.03$2.24
Low Forecast$-3.34$-4.83$-2.98$-2.99$-4.49$-4.63$-3.20$0.81
Surprise %4.40%-0.60%9.81%0.70%50.61%---

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$9.33M$9.22M$9.56M$10.90M$18.75M---
Avg Forecast$9.51M$8.32M$19.58M$9.74M$7.11M$21.89M$307.80M$861.96M
High Forecast$11.16M$11.13M$46.62M$12.09M$9.67M$22.88M$418.75M$1.17B
Low Forecast$7.87M$5.87M$5.92M$7.46M$4.54M$20.90M$196.62M$550.63M
Surprise %-1.98%10.84%-51.17%11.87%163.95%---

Net Income Forecast

$-700M $-520M $-340M $-160M $20M $200M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-118.01M$-174.00M$-212.22M$-322.30M$-684.63M---
Avg Forecast$-199.05M$-245.03M$-212.22M$-207.69M$-253.46M$-248.49M$-118.09M$111.56M
High Forecast$-154.36M$-151.35M$-136.14M$-197.17M$-179.08M$-158.64M$-2.51M$163.85M
Low Forecast$-243.66M$-352.61M$-217.24M$-218.20M$-327.84M$-338.34M$-233.67M$59.18M
Surprise %-40.71%-28.99%-55.19%170.11%---

RNA Forecast FAQ

Is Atrium Therapeutics stock a buy?

Atrium Therapeutics stock has a consensus rating of Buy, based on 16 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 8 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Atrium Therapeutics is a favorable investment for most analysts.

What is Atrium Therapeutics's price target?

Atrium Therapeutics's price target, set by 16 Wall Street analysts, averages $22.5 over the next 12 months. The price target range spans from $15 at the low end to $25 at the high end, suggesting a potential 174.39% change from the previous closing price of $8.2.

How does Atrium Therapeutics stock forecast compare to its benchmarks?

Atrium Therapeutics's stock forecast shows a 174.39% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Atrium Therapeutics over the past three months?

  • October 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Atrium Therapeutics’s EPS forecast?

Atrium Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-3.57, marking a -28.17% decrease from the reported $-4.97 in 2025. Estimates for the following years are $-1.85 in 2027, and $1.53 in 2028.

What is Atrium Therapeutics’s revenue forecast?

Atrium Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $21.89M, reflecting a 16.71% increase from the reported $18.76M in 2025. The forecast for 2027 is $307.8M, and $861.96M for 2028.

What is Atrium Therapeutics’s net income forecast?

Atrium Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-248M, representing a -63.70% decrease from the reported $-685M in 2025. Projections indicate $-118M in 2027, and $111.56M in 2028.